Using proteomics to advance understanding of Alzheimer’s disease
Using proteomics to advance
understanding of alzheimer’s disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
You’ll learn how mass spectrometry-based proteomics provides insights into brain changes and assists biomarker discovery in cerebrospinal fluid and plasma, and discover the potential of affinity-based proteomics for reliable biomarker identification. Our expert speaker will delve into intricate networks like proteostasis and the matrisome, highlighting their implications for therapeutic development.
Attend this webinar to:
- Gain insights into the landscape of AD brain changes using unbiased mass spectrometry-based proteomics
- Learn about biomarker discovery in AD cerebrospinal fluid and plasma through multi-platform proteomic analysis
- Understand the potential of affinity-based proteomics, including modified aptamer technology, in identifying reliable biomarkers for AD
- Explore the intricate networks associated with AD pathology and their implications for therapeutic development
Erik Johnson, MD, PhD
Assistant Professor, Department of Neurology
Emory University
Erik Johnson, MD, PhD, is an Assistant Professor in the Department of Neurology and a member of the Goizueta Alzheimer’s Disease Research Center and Center for Neurodegenerative Diseases at Emory University. He is a cognitive neurologist with an active clinical practice who sees patients with Alzheimer’s disease and other cognitive disorders. His research interests focus on using proteomics to understand the biochemical mechanisms that underlie Alzheimer’s disease and to develop molecular fluid biomarkers for these pathological changes. He is actively involved in large consortium research efforts on AD including the Accelerating Medicine Partnership – Alzheimer’s Disease (AMP-AD) consortium and the Dominantly Inherited Alzheimer Disease (DIAN) consortium.
Using proteomics to advance understanding of alzheimer’s disease
A presentation by Erik Johnson, MD, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.